Logo

SKIN

The Beauty Health Company

SKIN

The Beauty Health Company • NASDAQ
$1.48 ▲ 2.07% (+0.03)
Market Cap $188.70 M
52w High $2.69
52w Low $0.78
Dividend Yield 0%
P/E -9.25
Volume 212.72K
Outstanding Shares 127.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $70.655M ▼ $51.876M ▲ $-11.031M ▼ -15.612% ▼ $-0.09 ▼ $4.099M ▼
Q2-2025 $78.187M ▲ $51.812M ▼ $19.712M ▲ 25.211% ▲ $0.16 ▲ $28.264M ▲
Q1-2025 $69.58M ▼ $60.603M ▲ $-10.096M ▲ -14.51% ▼ $-0.081 ▲ $-542K ▲
Q4-2024 $83.495M ▲ $59.503M ▼ $-10.33M ▲ -12.372% ▲ $-0.083 ▲ $-2.696M ▲
Q3-2024 $78.802M $62.164M $-18.291M -23.211% $-0.15 $-4.319M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $219.397M ▲ $503.636M ▼ $437.976M ▲ $65.66M ▼
Q2-2025 $212M ▼ $507.565M ▼ $433.563M ▼ $74.002M ▲
Q1-2025 $373.031M ▲ $673.82M ▼ $627.759M ▼ $46.061M ▼
Q4-2024 $370.063M ▲ $685.683M ▼ $633.88M ▼ $51.803M ▼
Q3-2024 $358.892M $699.548M $639.824M $59.724M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.031M ▼ $9.647M ▲ $-1.084M ▲ $-803K ▲ $7.397M ▲ $9.62M ▼
Q2-2025 $19.712M ▲ $9.646M ▲ $-1.552M ▼ $-173.361M ▼ $-161.031M ▼ $10.791M ▲
Q1-2025 $-10.096M ▲ $2.996M ▼ $-1.145M ▼ $-250K ▲ $2.968M ▼ $1.851M ▼
Q4-2024 $-10.33M ▲ $16.472M ▲ $-862K ▲ $-770K ▼ $11.171M ▲ $15.61M ▲
Q3-2024 $-18.291M $10.315M $-2.092M $-204K $9.348M $8.223M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Consumables
Consumables
 $110.00M ▲$50.00M ▼$60.00M ▲$50.00M ▼
Delivery Systems
Delivery Systems
 $60.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement The business has grown quickly from a small base, but the income statement shows an inconsistent path to profitability. Revenue climbed strongly in the early years, then flattened and slipped more recently, suggesting that growth is no longer on a straight upward trajectory. The company usually earns healthy gross profits on what it sells, but operating costs have been high enough to keep most years in the red. There was a brief period of bottom‑line profitability, but losses returned afterward, which points to challenges in scaling sales, marketing, and overhead efficiently. Overall, the income statement tells a story of an attractive product platform that has not yet translated into steady, durable earnings.

Balance Sheet

Balance Sheet The balance sheet shows a business with decent total assets but relatively thin equity and a meaningful amount of debt. Cash once represented a very large cushion but has been drawn down over time, though it still sits at a significant level compared with the size of the company. Debt levels are high relative to the equity base and have not come down, which adds financial risk and puts pressure on future cash generation. Equity has improved from negative levels in 2020 to positive, but it remains slender, leaving less room for error if results disappoint or if the company needs more investment.

Cash Flow

Cash Flow Cash flow has been gradually improving but remains fragile. After several years of cash burn from operations, the business has recently managed to produce modest positive operating cash flow and free cash flow, helped by controlled investment spending. Capital spending needs appear manageable, which is a plus. However, the margin of safety is small: cash inflows from the business are not yet robust, and ongoing interest obligations and growth investments could quickly swing cash flow back into negative territory if performance softens.

Competitive Edge

Competitive Edge The company holds a distinctive spot in professional aesthetics, anchored by the HydraFacial brand and its patented delivery technology. Its core device‑plus‑consumables model creates recurring revenue from serums and tips, deepening relationships with clinics and spas. Strong brand recognition among skincare professionals, a wide installed base of devices, and meaningful switching costs once providers are trained and equipped all support a solid competitive moat. Partnerships with well‑known skincare brands and retailers further enhance visibility. The main competitive risks are copycat technologies, alternative treatment methods, and the need to keep providers engaged and loyal as new options appear.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. The company continues to build on its HydraFacial platform with connected devices like Syndeo, data‑driven personalization, and a growing menu of booster serums often co‑developed with recognized skincare brands. Moves into adjacent treatments such as microneedling and regenerative‑style boosters show an effort to broaden its treatment ecosystem and deepen wallet share with existing providers. The opportunity is to turn this pipeline into repeatable revenue and pricing power; the risk is that R&D and launch costs stay high without delivering enough incremental profitability or that new technologies fail to gain broad clinical and consumer adoption.

Summary

Overall, SKIN looks like a specialized beauty‑health platform with clear product differentiation and an expanding treatment ecosystem, but financials that still reflect an early‑to‑mid stage growth story rather than a mature, steadily profitable company. The top line shows that demand exists, but recent revenue softness and recurring net losses highlight execution and cost‑control challenges. The balance sheet offers some cash flexibility but is burdened by notable debt and limited equity, putting more weight on the company’s ability to keep improving cash generation. Long‑term potential depends on whether management can convert its strong brand, patented technology, and innovation pipeline into more stable growth, stronger margins, and consistently positive cash flow, all while managing leverage and competitive pressures in a fast‑moving aesthetics market.

NEWS

November 3, 2025 · 4:05 PM UTC

BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors

Read more

October 27, 2025 · 8:00 AM UTC

Halper Sadeh LLC Encourages The Beauty Health Company Shareholders to Contact the Firm to Discuss Their Rights

Read more

October 23, 2025 · 10:00 AM UTC

BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025

Read more

September 30, 2025 · 4:30 PM UTC

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Read more

September 23, 2025 · 8:00 AM UTC

Hydrafacial Joins Cosmopolitan Readers' Choice Hall of Fame as Three-Time Winner for Best Pro Facial

Read more